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Abstract
Background: To evaluate the clinical and economic impact of a specialty care management program among patients
with multiple sclerosis.
Methods: This retrospective cohort analysis included patients aged  18years with  2 claims of multiple sclerosis
diagnosis and  1 multiple sclerosis medications from 1 January 2004 to 30 April 2008. The outcome metrics included
medication adherence and persistence, multiple sclerosis-related hospitalization, and multiple sclerosis-related cost.
Multivariate analyses were performed to adjust for demographics and clinical characteristics.
Results: Among the 3993 patients identified, 78.3% participated in the program and 21.7% did not. Over 12months,
medication adherence and persistence improved among participants but deteriorated among non-participants (medica-
tion possession ratio change: þ0.08 vs  0.03, p<0.001; persistence change: þ29.2 days vs  9.2 days, p<0.001).
Multiple sclerosis-related hospitalization decreased from 9.6% to 7.1% for participants, whereas it increased from
10.1% to 12.0% for the non-participant group (p<0.001). Multiple sclerosis-related medical spending (non-pharmacy)
decreased among participants, but it increased among non-participants (mean:  US$264 vsþUS$1536, p<0.001). Total
multiple sclerosis-related cost for both groups increased over time (þUS$4471 vs þUS$4087, p<0.001).
Conclusions: This program was associated with improved medication adherence and persistence, reduced multiple
sclerosis-related hospitalization, and decreased multiple sclerosis-related medical costs. Unfortunately, the cost savings in
the medical component did not offset the increased pharmacy expenditures during the 12-month follow-up period.
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Introduction
Multiple sclerosis (MS) is a chronic and progressive
inﬂammatory disease of the central nervous system
that aﬀects approximately 211,000 to 400,000 people
in the United States of America.
1–3 It is characterized
by many uncertainties. The cause is relatively unknown,
the pathophysiological mechanisms are diverse, and the
disease course is highly variable.
4,5 In addition to the
disease uncertainty and complexity, patients with MS
experience a wide range of symptoms including fatigue,
cognitive dysfunction, bowel and bladder dysfunction,
weakness, spasticity, sexual dysfunction, and visual
problems.
4,5
Despite the availability of disease-modifying therapy
(DMT) since 1993, the management of MS remains
challenging. With no cure available, treatment and dis-
ease management focus on slowing progression and
preventing relapse as well as controlling symptoms.
6,7
Although the treatment eﬃcacy has been established,
adherence to pharmacotherapy remains one of chal-
lenges because of diﬃcult side-eﬀects. To meet this
need and improve the management of MS, a specialty
care management program has been introduced in one
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USA since July of 2005. The intervention includes mail-
ing medication and disease-speciﬁc patient education
materials directly to the patients. Nurses make assess-
ment calls at the beginning and follow-up assessments
at months 3, 6, and 12, and every 12months thereafter.
They serve as a liaison to the pharmacy, a source of
medical information, and a cheerleader to encourage
adherence despite frequent diﬃcult medication side-
eﬀects. The program also includes reﬁll reminder
calls. These calls enforce the importance of medication
compliance, inquire about patient’s status and develop
a relationship with the patient.
Many studies have reported the potential beneﬁts of
care management programs in other therapeutic areas
such as diabetes, congestive heart failure, coronary
artery disease, and asthma.
8–12 However, relatively
little published evidence about MS care management
programs is available. Some earlier studies have
shown the feasibility of programs for patient education,
exercise, specialist nurse, depression disease manage-
ment, and energy conservation among people with
MS.
13–17 Most of these studies were symptom speciﬁc
and few were conducted on a wide scale. There is a need
to understand the impact of this type of program and
facilitate informed decision-making for review and
implementation. This study aims to address this exist-
ing gap. The primary study hypothesis is that the spe-
cialty care management program is associated with
medication adherence and persistence, risk of
MS-related hospitalization, and MS-related cost of
care. To our knowledge, this is the ﬁrst study to eval-
uate the eﬀectiveness of a specialty care management
program on these clinical and economic outcomes
among patients with MS.
Methods
Data source
This is a retrospective cohort study using administra-
tive claims data from the HealthCore Integrated
Research Database (HIRD
SM), which includes 13 geo-
graphically dispersed US commercial health plans,
providing coverage for approximately 24.2 million
members. The administrative data set consists of inte-
grated medical claims, pharmacy claims, and eligibility
ﬁles. The study database was developed in compliance
with Health Insurance Portability and Accountability
Act of 1996 regulations (HIPAA).
Patient selection
The study population included those members aged
18 or above with at least two medical claims with an
International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) code for MS (ICD-
9-CM: 340.xx) and at least one medical or prescription
claim for MS medication between 1 January 2004 and
30 April 2008. MS medications of interest included
interferon beta-1a (both intramuscular (IM) and sub-
cutaneous (SC)), interferon beta-1b, glatiramer acetate,
mitoxantrone, and natalizumab. For patients enrolled
in the specialty care management program (participant
group), the index date was deﬁned as the start date of
program participation. As other patients (non-partici-
pant group) did not have a program participation start
date, an index date was randomly assigned through
Monte Carlo simulation with regard to the participant
patients on treatment history (length of time from the
ﬁrst observed MS treatment to program participation)
to maximize the comparability of treatment history
between participant and non-participant groups for
subsequent evaluation. Non-participants included
those who elected to obtain their medications from
other sources, those who resided in geographical
regions where the care management was not imple-
mented at the time of this study, and/or those who
participated in other care management programs
which cannot be identiﬁed in the database. All patients
were required to have  12months of continuous health
plan enrollment prior to and after index date.
Study measures
Three outcomes were assessed: medication adherence
and persistence, MS-related hospitalization, and total
MS-related cost of care during the 12months post-
index period. Medication adherence was measured
using medication possession ratio (MPR), deﬁned as
the ratio of the total days supply of medication dis-
pensed during the period to the total number of days
over the post-index 12-month period.
18,19 Medication
persistence referred to the duration of time from initi-
ation to discontinuation of therapy,
18,19 where discon-
tinuation was deﬁned as failing to obtain any MS
medication within 60 days after the depletion of the
previous days’ supply. MS-related hospitalization was
measured through identiﬁcation of inpatient hospitali-
zations from medical claims in which there were any
claims containing an ICD-9-CM code for MS. Total
MS-related cost of care reﬂected the total allowable
amount reimbursed by the health plans, which con-
sisted of both medical and pharmacy components.
The medical component included cost incurred in inpa-
tient, emergency room, and outpatient settings associ-
ated with an ICD-9-CM code for MS. The pharmacy
component referred to the cost of MS medications ﬁlled
or administered (interferon beta-1a, interferon beta-1b,
glatiramer acetate, mitoxantrone, and natalizumab).
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All outcome measures were compared between the
participant and non-participant groups. Statistical dif-
ferences between groups were assessed using Wilcoxon
rank-sum test for continuous variables and Pearson
Chi-square test for categorical variables. An a priori
two-tailed level of signiﬁcance (alpha value) was set at
the 0.05 level for all analyses.
Multivariate analyses were performed to evaluate
the association between the intervention of the specialty
care management program and each outcome while
controlling for potential confounders. Generalized
linear models were constructed using various response
probability distributions and link functions, depending
on the distribution of the outcomes and goodness of
ﬁt of the models. For instance, gamma distribution
and log link function were used for total cost of care,
while binomial distribution and logit link function were
used for hospitalization. Covariates were chosen a
priori for all models based on clinical relevance and
baseline diﬀerences, which included age, gender, geo-
graphical region, plan type (i.e. health maintenance
organization (HMO), preferred provider organization
(PPO)), Deyo–Charlson co-morbidity index, co-morbid
conditions (numbness, fatigue, abnormality of gait, and
depression), the ﬁrst MS medication on or after index
date (i.e. interferon beta-1a, glatiramer acetate), length
of treatment history (number of days between the ﬁrst
observed MS medication and index date), and baseline
health care utilization (hospitalization and cost).
Results
A total of 3993 patients with MS were identiﬁed. Of
them, 78.3% (n¼3125) participated in the specialty
care management program and 21.7% (n¼868) did
not. Overall, the mean age was 46.3 9.6years and
approximately three-quarters of the cohort (75.2%)
were female. Interferon beta-1a IM was the most
common MS medication used (37.3%), followed by
glatiramer acetate (31.4%), interferon beta-1a SC
(16.6%), interferon beta-1b (13.5%), natalizumab
(0.8%), and mitoxantrone (0.5%). The participants
and non-participants were comparable in terms of
age, Deyo–Charlson co-morbidity index, and baseline
co-morbid conditions (Table 1). Compared with non-
participants, the participant patients had slightly
more females, were covered by diﬀerent health
plans types (i.e. more HMO), had diﬀerent geo-
graphic distribution, and had slightly higher propor-
tion of beta-1a IM and glatiramer acetate use. Based
on the time from ﬁrst observed MS medication to
index date, the participant group had a slightly
longer treatment history than the non-participant
group (mean 16.8months vs 14.6months, respectively,
p<0.001).
During the 12-month period after the index date,
medication adherence was signiﬁcantly better in the
participant group than the non-participant group
(mean MPR: 0.86 vs 0.64, p<0.001, Table 2).
Compared with the 12-month period prior to index
date, the MPR increased signiﬁcantly more among
the participants than the non-participants (mean
þ0.08 vs  0.03, p<0.001). In multivariable regression
analysis controlling for pre-index characteristics
(including pre-index MPR), the participant group on
average had 0.18 (95% conﬁdence interval (CI): 0.16–
0.19) higher MPR than the non-participant group.
Similarly, the participants were more persistent on
MS therapy (time from initiation to discontinuation
of therapy) than the non-participants (mean 306.1
days vs 246.9 days, p<0.001, Table 2). Over time, the
average time from initiation to discontinuation of ther-
apy of participant group increased by 29.4 days, while it
decreased by 9.2 days in the non-participant group
(p<0.001). When pre-index characteristics were con-
trolled for in multivariate analysis, the participants on
average had a mean medication persistence of 50.6
(95% CI: 43.1–58.2) days longer than the non-
participants.
During the 12-month period prior to the index date,
participant and non-participant groups had compara-
ble MS-related hospitalization rates (9.6% vs 10.1%,
p¼0.64, Figure 1). However, the MS-related hospital-
ization rate became signiﬁcantly lower for participants
than that for non-participants during the 12-month
period after index date (7.1% vs 12.0%, p<0.001).
Multivariable logistic regression analysis also showed
the consistent trend that the participants were signiﬁ-
cantly less likely to have a MS-related hospitalization
during the 12-month period after index date (adjusted
odds ratio: 0.51, 95% CI: 0.39–0.67).
Over 12months, the average MS-related medical
costs (non-pharmacy) decreased by US$264 among
participants, while it increased US$1536 among non-
participants (p<0.001, Figure 2). On the other hand,
the average MS-related pharmacy costs increased over
time for both groups, with greater increases in the par-
ticipant group (US$4735 vs US$2551, p<0.001).
Summing up the MS-related medical and pharmacy
costs, the participant group had a larger increase in
MS-related total cost of care from pre- to post-period
than the non-participant group (US$4471 vs US$4087,
p<0.001, Figure 3). The same trend was found in mul-
tivariate analysis results. After adjusting for baseline
characteristics, the participants had 21% (95% CI:
17%–26%) higher MS-related total cost of care than
non-participants during the 12-month period after
index date.
958 Multiple Sclerosis 16(8)Discussion
The MS specialty care management program had sub-
stantial impact on MS management in this large, com-
mercially insured population. It was associated with
improved medication adherence and persistence,
reduced MS-related hospitalization, decreased MS-
related medical costs, and increased MS-related total
cost of care. These ﬁndings were encouraging, espe-
cially given the relatively short follow-up period of
1year. Many times, the eﬀects of disease manage-
ment take years to become evident in patient outcomes,
utilization of health care services, and economic
outcomes.
9
One year after enrollment of the program, the par-
ticipants’ medication adherence and persistence were
improved. Even though participants’ adherence
appeared to be better at the baseline, it improved sig-
niﬁcantly more within a year (on average increased
29.2 days, converted from 0.08MPR) while the adher-
ence deteriorated among non-participants. This obser-
vation was further substantiated with similar ﬁndings in
persistence on medication. Given equivalent persistence
at the baseline, the participants’ persistence on MS
medication improved during the 12-month period
after index date, whereas the non-participants’ persis-
tence worsened in the same period ( þ29.4 days vs
 9.2 days). Adherence has been crucial for obtaining
Table 1. Baseline patient characteristics (n¼3993)
Patient Characteristics Participant Non-participant p-value
Number of patients, n (%) 3125 (78.3) 868 (21.7)
Age, mean SD (median) 46.4 9.3 (47.1) 45.9 10.5 (46.1) 0.10
Female, % 76.4 71.0 0.001
Health plan region, % <0.001
East 15.6 24.9
Central 36.5 20.9
South 25.0 31.8
West 22.9 22.5
Health plan type, % <0.001
HMO 16.9 26.8
POS 7.8 7.7
PPO 69.1 52.9
Others 6.21 12.6
DCI score
a, mean SD (median) 0.32 0.85 (0) 0.34 0.85 (0) 0.13
Co-morbid conditions, %
Fatigue 16.8 17.3 0.74
Numbness 16.6 15.3 0.38
Depressive and mood disorders 41.7 44.1 0.21
Ataxia 3.0 1.8 0.06
Abnormality of gait 6.4 7.3 0.35
Fibromyalgia/myalgia and myositis 3.7 5.0 0.08
Urinary incontinence 3.6 2.5 0.13
Time from first observed MS
treatment to index date (months),
mean SD (median)
16.8 10.1 (19.0) 14.6 9.8 (16.4) <0.001
MS medication
b,% <0.001
Interferon beta-1a IM 37.7 35.8
Interferon beta-1a SC 16.7 16.0
Interferon beta-1b 13.1 14.8
Glatiramer acetate 31.8 29.8
Natalizumab 0.5 1.8
Mitoxantrone 0.2 1.7
aDeyo–Charlson co-morbidity index.
bThe first observed MS medication on or after index date.
Tan et al. 959the beneﬁcial eﬀects of treatment, as is true for other
therapeutic areas.
20 These results suggested that the
program had a positive impact on patient adherence
and persistence with MS medication, and might conse-
quently obtain greater treatment beneﬁts.
During the 12-month period after enrollment, the
MS-related hospitalization rate for the participant
group dropped from 9.6% to 7.1%, whereas it
increased from 10.1% to 12.0% in the non-participant
group. This considerable reduction in hospitalization
risk among participants was encouraging, especially
given that both groups had comparable MS-related
hospitalization rates during the baseline period (9.6%
vs 10.1%, p¼0.64). This reduction in MS-related hos-
pitalizations represents a successful improvement in
clinical beneﬁts of the program, as these hospitaliza-
tions serve as an indicator of severe MS exacerbation
and acute care service. The reduced risk also coincided
with improved adherence and persistence among par-
ticipants in the same period, which suggested that the
improved clinical outcomes might be a result of better
control in disease progression.
After 1year of enrollment in the program, the par-
ticipants decreased their average MS-related medical
spending by US$264, as opposed to non-participants
Table 2. Medication adherence and persistence 12-month period prior to and after index date
Outcome Measures Participant Non-participant p-value
MPR
a
Pre-index 12months
b, mean SD (median) 0.78 0.28 (0.92) 0.68 0.32 (0.82) <0.001
Post-index 12months
c, mean SD (median) 0.86 0.20 (0.99) 0.64 0.33 (0.74) <0.001
Change (post–pre)
d, mean SD (median) 0.08 0.31 (0.01)  0.03 0.30 (0) <0.001
Time from initiation to discontinuation of therapy
e (days)
Pre-index 12months
b, mean SD (median) 275.0 112.1 (336) 261.2 125.3 (338) 0.76
Post-index 12months
c, mean SD (median) 306.1 84.1 (343) 246.9 129.6 (334) <0.001
Change (post–pre)
d, mean SD (median) 29.4 124.4 (12)  9.2 142.6 (0) <0.001
aMedication possession ratio.
bAmong 88.9% (n¼2778) participants and 82.3% (n¼714) non-participants used one or more MS medication during this period.
cAmong 99.1% (n¼3097) participants and 96.8% (n¼840) non-participants used one or more MS medication during this period.
dAmong 88.4% (n¼2761) participants and 80.3% (n¼697) non-participants used one or more MS medication during both pre- and post- 12 months
period.
eDiscontinuation was defined as failing to obtain medication within 60days after the depletion of the previous days supply.
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Figure 2. MS-related medical and pharmacy costs 12 month
period prior to and after index date.
Participant
Non participant
Pre-
p=0.64
Post-
p<0.001
14.0%
12.0%
12.0%
10.0%
10.1%
7.1% 8.0%
9.6%
6.0%
4.0%
2.0%
0.0%
Figure 1. MS-related hospitalization 12-month period prior to
and after index date.
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the potential cost savings of the program by avoiding
unnecessary medical utilization including hospitaliza-
tion, emergency department, and unscheduled oﬃce
visits. On the other hand, the pharmacy expenditure
increased in both groups over time, with greater mag-
nitude among participants. The greater increase was
expected in part because of improved medication
adherence and persistence among participants. When
summing up MS-related medical and pharmacy costs,
however, the savings in medical utilization, unfortu-
nately, did not oﬀset the increased pharmacy spending
for participants during the 12-month post-observation
period. This could be largely explained by the fact that
MS medications constituted about 72.3% (non-partici-
pants) to 84.0% (participants) of the MS-related total
cost of care, which was in line with other studies show-
ing that pharmacy costs accounted for the majority of
the MS-related total cost.
21,22 As a result, it is unlikely
that a long-term cost saving will be seen in MS-related
total cost for participants, unless there is a signiﬁcant
drop in medication costs in the future. Nonetheless,
it is important to note that such a program is worth-
while even if it does not lead to overall cost reduction.
In fact, it does not discount the clinical beneﬁts
observed in medication adherence and hospitalization
in this study.
This study did not evaluate patient-reported out-
comes. Thus, the eﬀect of the program on other out-
comes such as functional status and absenteeism was
unclear. Other studies had shown the potential impact
of care management program on quality of life, lost
work/school days, and patient satisfaction in other
therapeutic areas.
10,23–25 One could speculate that the
improved medication adherence and persistence,
reduced risk of MS-hospitalization, and decreased
MS-related medical spending observed in this study
might have aﬀected patients’ quality of life, productiv-
ity, and disease progress. With decreasing medical care
utilization indicated by both reducing MS-related hos-
pitalizations and medical spending, patients’ mobility
level and functional status may have been better con-
trolled and disease progress may have slowed down.
As a result, we hypothesize that the long-term health
of these MS patients would be more stable than if they
had not participated in the program. The reduction of
medical utilization also leads us to believe that the MS
patients would have fewer MS-related absences from
work and family-related responsibilities. However, fur-
ther research will be needed to substantiate these
hypotheses.
To validate the robustness of the study ﬁndings, we
performed several sensitivity analyses with diﬀerent
methods. These methods included a) using all-cause
hospitalization instead of MS-related hospitalization;
b) using all-cause total cost instead of MS-related
total cost; c) excluding patients over 65years old;
and d) excluding patients on mitoxantrone and natali-
zumab. All results of these sensitivity analyses were
consistent with the primary results and did not alter
the overall conclusions of this study.
Limitations
The study ﬁndings are subject to several limitations.
First, randomization of intervention (care manage-
ment) was not performed due to the nature of observa-
tional study. Although the comparability between
participants and non-participants in unobserved char-
acteristics (such as MS types (i.e. relapsing–remitting,
primary–progressive), disability level) cannot be assu-
med, the fact that over time change comparison still
reﬂected the potential impact of the program increases
the chance that the current results are robust. Second,
misclassiﬁcation or measurement error could occur in
administrative claims, but it is unlikely that such error
would be systematically diﬀerent across cohorts. Third,
the disenrollment information from the program was
not available. The participant group might have
included those who only partially participated or
dropped out sometime after enrollment in the program,
and hence the program eﬀect observed in this study
could be underestimated. Fourth, it could be argued
that the results might not be generalizable to non-
participants due to diﬀerence in unmeasured character-
istics such as self-motivation and health-consciousness.
The participants may already have been more moti-
vated so that the management program was an add-
on. Nonetheless, this does not refute the observation
that the program aﬀects participants as an aggregate,
who accounted for 78.3% in this commercially insured
population.
Pre-
p<0.001
Post-
p<0.001
$20,000
$25,000
$15,000 $15,688
$20,159
$16,894
$4,471
$4,087
$12,807
Participant
Non-participant
$10,000
$5,000
$0
Figure 3. MS-related total cost of care 12-month period prior
to and after index date.
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To our knowledge, this study was the ﬁrst to evaluate
the impact of a MS specialty care management pro-
gram on clinical and economic outcomes. Our ﬁndings
suggested that this program was associated with
improved medication adherence and persistence,
reduced risk of MS-related hospitalization, and
decreased MS-related medical costs (excluding phar-
macy) over time. This represented an important
metric of program success. It was also associated with
higher MS-related total cost of care, which was primar-
ily driven by high pharmacy costs. The cost saving
in medical utilization, unfortunately, did not oﬀset
the increased expenditure in pharmacy during the
12-month period after the program intervention.
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